FRM
CSTL icon

Fox Run Management’s Castle Biosciences CSTL Stock Holding History

Fox Run Management’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$618K Buy
26,247
+4,363
+20% +$143K 0.11% 350
2025
Q4 		$851K Buy
21,884
+8,064
+58% +$260K 0.13% 274
2025
Q3 		$315K Buy
+13,820
New +$281K 0.05% 663
2025
Q1 		– Sell
-10,716
Closed -$286K – 962
2024
Q4 		$286K Buy
+10,716
New +$326K 0.05% 652
2024
Q1 		– Sell
-12,150
Closed -$262K – 806
2023
Q4 		$262K Buy
+12,150
New +$214K 0.07% 544

Other funds holding CSTL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $3.72B AUM 162.29% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fox Run Management's CSTL Position: Q1 2026 in Review

Fox Run Management increased its Castle Biosciences (CSTL) stake by 20% in Q1 2026, buying an estimated $143K and bringing the position to 26,247 shares worth $618K. The position accounts for 0.11% of the portfolio, ranked #350.

Fox Run Management first reported a position in CSTL in Q4 2023 and has held it in 5 quarters since. The position peaked at $851K in Q4 2025. 186 funds tracked by Wall St. Rank hold CSTL as of Q1 2026.

  • Fox Run Management held 26,247 shares of Castle Biosciences worth $618K as of Q1 2026.
  • Fox Run Management bought 4,363 Castle Biosciences shares in Q1 2026, an estimated $143K.
  • Castle Biosciences made up 0.11% of Fox Run Management's portfolio in Q1 2026, its #350 holding.
  • Fox Run Management first reported a position in Castle Biosciences in Q4 2023 and has held it in 5 quarters since.
  • Fox Run Management's Castle Biosciences position peaked at $851K in Q4 2025.
  • 186 funds tracked by Wall St. Rank held Castle Biosciences as of Q1 2026.

Based on Fox Run Management's 13F filing for Q1 2026, filed 12 May 2026.